Bryostatin 1 In Treating Patients With Progressive Kidney Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00005056|
Recruitment Status : Completed
First Posted : August 9, 2004
Last Update Posted : June 26, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have progressive kidney cancer
|Condition or disease||Intervention/treatment||Phase|
|Kidney Cancer||Drug: bryostatin 1||Phase 2|
OBJECTIVES: I. Determine the response rates in patients with progressive hypernephroma treated with bryostatin 1. II. Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study. Patients receive bryostatin 1 IV over 24 hours on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. For patients with stable or responding disease after completion of course 2, treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study within 12-18 months.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Phase II Trial of Bryostatin-1 in Hypernephroma|
|Study Start Date :||March 1999|
|Actual Study Completion Date :||July 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005056
|Oxford Radcliffe Hospital|
|Oxford, England, United Kingdom, 0X3 7LJ|
|Imperial Cancer Research Fund Medical Oncology Unit|
|Oxford, England, United Kingdom, OX3 7LJ|
|Study Chair:||Adrian L. Harris, MD||Oxford University Hospitals NHS Trust|